[ad_1]
Antônio Barra Torres (Anvisa) and Dimas Tadeu Covas (Butantã) can be heard on the suspension of Coronavac production in two hearings this Friday (13)
The Joint Commission of Congress that accompanies the measures related to the new coronavirus approved this Wednesday (11) two requirements for invitation to public hearings. The first is for the director general of the National Electric Energy Agency (Aneel), André Pepitone da Nóbrega. The second, for its part, invites the director-president of the National Health Surveillance Agency (Anvisa), Antônio Barra Torres and the director of the Butantan Institute, Dimas Tadeu Covas, to provide clarifications on the suspension of clinical studies of the vaccine CoronaVac.
Due to the urgency of the two issues, the intention of the president of the college, Senator Confúcio Moura (MDB-RO), is that the two hearings be held this Friday (13), but the confirmation of the date will depend on the availability of the authorities.
In the case of the general director of Aneel, the parliamentarians want André Pepitone to clarify the causes of the failure of the electrical system, the failure in the reserve system and the measures taken to restore the normality of the electricity supply in the state.
The federal government released R $ 21.6 million yesterday for Civil Defense actions in Amapá. The funds, according to the governor, Waldez Goes, will be used to rent generators and buy fuel. The state has faced power supply problems since November 3, when a fire in a substation caused a blackout in 13 of the state’s 16 municipalities, including the capital, Macapá. As a result, other services to the population were also affected, such as water supply and communications, in addition to the impact on essential sectors, such as health and public safety.
CoronaVac
The parliamentarians want to hear from the representatives of Anvisa and Butantan to clarify the interruption of the clinical studies of the CoronaVac vaccine. On Monday night (9), Anvisa announced the interruption of the studies, after receiving information from the Butantan Institute that a “serious adverse event” had occurred with one of the study volunteers.
Although neither Anvisa nor Butantan confirm it, the event would be suicide and would not be related to the vaccine for the laboratory that performs the tests.
On the morning of yesterday (10), both institutions held press conferences to clarify the sequence of events that also included a delay in the communication of Butantan to Anvisa, supposedly for reasons related to a hacker attack last week, which affected the Ministry of Health system.
Anvisa recently published a note announcing the resumption of CoronaVac clinical trials.
[ad_2]
